TDP43 Q331K

TDP-43 (TAR DNA-binding protein 43) is an RNA-binding protein essential for RNA metabolism, normally functioning in the cell nucleus. In ALS and FTD, TDP-43 misfolds and accumulates in toxic aggregates outside the nucleus, a pathological hallmark found in over 97% of ALS cases and nearly half of FTD cases [3]. The Q331K variant involves a change from glutamine to lysine at position 331, located in TDP-43's intrinsically disordered C-terminal domain (CTD), a region critical for both normal condensate formation and pathological aggregation [2][4]. The structural prediction for Q331K was generated using AlphaFold2/ColabFold methodology, yielding an average confidence score (pLDDT) of 64.6. This moderate-to-low confidence indicates substantial uncertainty in the predicted structure, particularly expected for the CTD region which is intrinsically disordered and lacks a stable folded structure [4]. Confidence scores below 70 indicate that specific structural details should be interpreted with considerable caution, as the model cannot reliably predict the conformation of disordered regions. The CTD's flexible nature is functionally important—it enables TDP-43 to undergo phase transitions into liquid-like condensates such as stress granules, but mutations in this region can drive aberrant transitions into solid, amyloid-like aggregates [2][4]. The Q331K substitution replaces a polar, uncharged glutamine with a positively charged lysine, potentially altering the electrostatic properties and phase behavior of the CTD. Research has shown that mutations in TDP-43's C-terminal alpha-helix region can uncouple normal condensate formation from pathological amyloid assembly [4], suggesting that charge changes like Q331K might similarly disrupt the protein's phase transition dynamics. Additionally, studies demonstrate that TDP-43 pathology involves complex molecular crosstalk with other proteins and is modulated by cellular factors that regulate phase behavior and nuclear-cytoplasmic transport [1][2], providing context for how single amino acid changes might trigger disease cascades. Given the low structural confidence and the inherently disordered nature of this protein region, the primary research value lies in recognizing Q331K as a variant in a functionally critical domain rather than in specific atomic-level structural predictions. The charge alteration from Q to K at position 331 occurs in a region where TDP-43's conformational dynamics directly influence its aggregation propensity and neurotoxic activity [2][4]. Understanding such variants contributes to the broader effort to identify biomarkers and therapeutic targets for ALS and FTD, conditions where distinguishing between TDP-43 and tau pathology is clinically important for guiding treatment strategies [3].